Pfizer ( VGK-A +0.65% ) said on Tuesday it would generate US$1.7-billion more in savings from cost-cutting to its ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in the Philippines, coinciding with its 175th-year global milestone.

Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission.

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

Researchers at Virginia Tech have found a way to make biodegradable packaging stronger while using less energy in the process. The research team from the College of Agriculture and Life Sciences ...

Advanced packaging has evolved far beyond the simple stacking of dies and connecting of interposers. Once a passive conduit between silicon and the outside world, it has become an active component of ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

open image in gallery Drugmaker Pfizer announced its decision to discontinue the development of its potential once-daily pill treatment for obesity, known as danuglipron. The decision came after a ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug. (Image Credits: Reuters) Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...